A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingOpportunities in low-level radiocarbon microtracing: applications and new technologyUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyVismodegib: in locally advanced or metastatic basal cell carcinoma.Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjectsSemi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor VismodegibHuman mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometryA clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.Profile of vismodegib and its potential in the treatment of advanced basal cell carcinomaHedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?Basal cell carcinoma: a paradigm for targeted therapies.Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.Investigational agents in metastatic basal cell carcinoma: focus on vismodegib.Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.Adding value through accelerator mass spectrometry-enabled first in human studies.Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.Absorption, Distribution, Metabolism and Excretion of mTOR kinase inhibitor CC-223 in Rats, Dogs and Humans.A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
P2860
Q23923997-8C7ADD16-12F5-4984-B32F-BEC19DE96442Q28817904-AC722156-0555-4DE5-9F8E-CC1186A3FD70Q28818313-DE5C6237-A535-4192-84CA-ECE056132DB2Q34032755-8CA12DBF-AB79-4BD2-82D9-F4E7DFE58DB3Q35846147-2C5577B0-BC0A-43BB-8065-1C3A8BA320F0Q36390239-2DE8A68F-F221-45BC-AC95-165085AF0E9AQ36473104-5F38AD62-FA5A-4E31-882A-648CE1437A1AQ36619557-97513B01-AED3-4681-88A6-CAB1D24095BBQ37038172-3017225B-5FDC-4C18-B06B-3302840EFC41Q37079100-CBF922D0-FA45-4E30-9BAC-D73AAF299781Q37551492-E63F1716-CFFD-4FCB-A186-7C94F44FBA4BQ38022125-48F308EE-1AEA-4F14-AAFD-1DC9C24214B0Q38105172-CFADBA10-9E2B-43D8-8E2F-9EDB3619EC22Q38164659-0022DC94-E161-41E5-BB33-AFCBDED2BF8CQ38836071-BA29BCF7-00C4-404A-B804-7A3EFE4AB3EBQ38836158-1CA2858B-52ED-4850-B6B6-5318F8C42B4BQ38842917-6E07B4D6-E0D8-43DB-9593-498367AB2CD4Q39573778-B2A66256-AECF-4294-ABDC-B407B11F175EQ41537666-DC09934E-0089-4E0C-917E-4C6B3C6772A3Q42509920-11090B1F-7F66-4154-B55E-37284713B4E8Q46247760-DDDCF1B4-4EA0-42A0-AC1D-A67700B29C3BQ48317730-90AECF3A-8DF5-4EAF-B4A6-355466CCDCEF
P2860
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A single dose mass balance stu ...... accelerator mass spectrometry.
@en
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib
@nl
type
label
A single dose mass balance stu ...... accelerator mass spectrometry.
@en
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib
@nl
prefLabel
A single dose mass balance stu ...... accelerator mass spectrometry.
@en
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib
@nl
P2093
P356
P1476
A single dose mass balance stu ...... accelerator mass spectrometry
@en
P2093
Bert L Lum
Brian Dean
Cornelis E C A Hop
Glenn Morrison
Ilsung Chang
Jennifer A Low
Karin Jorga
Richard A Graham
P304
P356
10.1124/DMD.111.039339
P50
P577
2011-05-20T00:00:00Z